NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $3.67 -0.08 (-2.13%) Closing price 11/19/2026 04:00 PM EasternExtended Trading$3.66 0.00 (-0.14%) As of 11/19/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.65▼$3.8550-Day Range$3.59▼$5.2152-Week Range$3.57▼$9.94Volume638,770 shsAverage Volume1.31 million shsMarket Capitalization$221.92 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company Overview Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders and other conditions. Headquartered in Washington, D.C., the company was founded in 2003. Its commercial products include Fanapt (iloperidone), approved in the United States for schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder, and Hetlioz (tasimelteon), used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome. Vanda also develops investigational medicines, including tradipitant, which it has studied for conditions such as motion sickness and gastroparesis. Its commercial activities are centered on the U.S. market.AI Generated. May Contain Errors. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreVNDA MarketRank™: 4.089720655015 of 5 starsVanda Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 73rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingVanda Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialVanda Pharmaceuticals has a consensus price target of $13.50, representing about 267.8% upside from its current price of $3.67.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($2.53) to ($0.94) per share.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.12% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 5.93.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 8.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentVanda Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vanda Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest5 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows3 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership4.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $38,069.00 in company stock, which represents 0.0172% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,069.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.70% of the stock of Vanda Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VNDA Stock News HeadlinesVanda Pharmaceuticals Earnings Call Signals Growth Amid RisksNovember 15, 2026 | theglobeandmail.comNEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art WeekNovember 11, 2026 | prnewswire.comUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it. | Profits Run (Ad)Insider Buying: Vanda Pharmaceuticals (NASDAQ:VNDA) Director Buys $13,167.54 in StockNovember 6, 2026 | insidertrades.comVanda Pharmaceuticals Announces Participation at November 2026 Investor ConferencesNovember 3, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Vanda (VNDA) and Viking Therapeutics (VKTX)October 30, 2026 | theglobeandmail.comVanda targets full-year 2026 total revenues greater than $240M as BYSANTI launch nears Q4October 29, 2026 | seekingalpha.comVanda (VNDA) Q3 2026 Earnings Call TranscriptOctober 29, 2026 | finance.yahoo.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $8.82 at the beginning of 2026. Since then, VNDA stock has decreased by 58.4% and is now trading at $3.67. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.31. The biopharmaceutical company had revenue of $69.82 million for the quarter, compared to the consensus estimate of $69.20 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 62.70% and a negative net margin of 119.87%. Read the conference call transcript. Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' top institutional investors include State Street Corp (4.98%), AIGH Capital Management LLC (3.72%), Marshall Wace LLP (3.44%) and Goldman Sachs Group Inc. (1.76%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Gunther Birznieks, Kevin Patrick Moran, Timothy Williams, Joakim Wijkstrom, Charles Cliff Duncan and Stephen Ray Mitchell. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Intel (INTC), Bristol Myers Squibb (BMY), Chevron (CVX) and Palantir Technologies (PLTR). Company Calendar Last Earnings10/28/2026Today11/19/2026Jefferies Global Healthcare Conference11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VNDA's financial health is in the Red zone, according to TradeSmith. VNDA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees533Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$13.50 High Price Target$20.00 Low Price Target$7.50 Potential Upside/Downside+267.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($4.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$220.47 million Net Margins-119.87% Pretax Margin-74.67% Return on Equity-62.70% Return on Assets-37.53% Debt Debt-to-Equity Ratio0.01 Current Ratio1.54 Quick Ratio1.53 Sales & Book Value Annual Sales$216.10 million Price / Sales1.03 Cash FlowN/A Price / Cash FlowN/A Book Value$3.31 per share Price / Book1.11Miscellaneous Outstanding Shares60,470,000Free Float54,000,000Market Cap$221.92 million OptionableOptionable Beta0.74 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:VNDA) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.